Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum92371Research ArticleEffektivnost' memantina dlya lecheniya bol'nykh s distsirkulyatornoy entsefalopatiey, perenesshikh insul'tSkvortsovaV. I-StakhovskayaL. V-DenisovaI. A-ShekhovtsovaK. V-KerbikovO. B-AlekseevaG. S-1502200792828628122021Copyright © 2007, Consilium Medicum2007[Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М., 2001.][Захаров В.В., Яхно Н.Н. Когнитивные расстройства в пожилом и старческом возрасте. М., 2005.][Преображенская И.С., Мхитарян Э.А., Дамулин И.В. Влияния мемантина на когнитивные функции у больных деменцией различной этиологии. Consilium Medicum. 2006.][Androsova L.V, Selezneva N.D. Akatinol memantin in Alzheimer's disease: clinico - immunological correlates Zh Nevrol Psikhiatr Im S S Korsakova. 2000; 100 (9): 36-8.][Danysz W, Parsons C.G, Mobius H.J et al. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease - a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res. 2000; 2 (2-3): 85-97.][Danysz W, Parsons C.G, Quack G. NMDA channel blockers: memantine and amino - aklylcyclohexanes--in vivo characterization. Amino Acids 2000; 19 (1): 167-72. Review.][Dingledine R, Borges K, Bowie D, Traynelis S.F. The glutamate receptor ion channels. Pharmacol Rev 1999; 51 (1): 7-61. Review.][Foy C.J, Passmore A.P, Vahidassr M.D et al. Plasma chain - breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease. QJM 1999; 92 (1): 39-45.][Kase C.S, Wolf P.A, Kelly-Hayes M et al. Intellectual decline after stroke: the Framingham Study. Stroke 1998; 29 (4): 805-12.][Mark L.P, Prost R.W, Ulmer J.L et al. Pictorial review of glutamate excitotoxicity: fundamental concepts for neuroimaging. AJNR Am J Neuroradiol 2001; 22 (10): 1813-24. Review.][Muller W.E, Mutschler E, Riederer P. Noncompetitive NMDA receptor antagonists with fast open - channel blocking kinetics and strong voltage - dependency as potential therapeutic agents for Alzheimer's dementia. Pharmacopsychiatry 1995; 28 (4): 113-24. Review.][Orgogozo J.M, Rigaud A.S, Stoffler A et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo - controlled trial (MMM 300).1: Stroke 2002; 33 (7): 1834-9.][Pohjasvaara T, Erkinjuntti T, Ylikoski R et al. Clinical determinants of poststroke dementia. Stroke 1998; 29 (1): 75-81.][Winblad B, Portis N. Memantine in severe dementia: results of the 9M-Best study. Int J Geriatr Psychiatry 1999; 14: 135-46.]